SynBioBeta’s Post

TechBio is the "New Wave" 🚀 With the aid of remarkable enabling technologies such as #AI and #ML, we're unlocking the immense potential of biology to heal, to feed and to provide for ourselves and for our planet. BUT, the biopharma industry faces challenges in aligning incentives and funding. Academic labs often struggle to secure funding for early career researchers and risky projects. This is where platforms like Molecule AG and VitaDAO address these issues by creating open ecosystems for community-driven research funding. Molecule was started by Tyler Golato and Paul Kohlhaas. At VitaDAO, among the main Contributors & Advisors are Vincent Weisser, Eleanor Davies and Paolo Binetti. In my latest newsletter, I delve into two amazing topics: TechBio & Decentralised Biotechnology. https://lnkd.in/eYHfmfjM Enjoy the reading! #Biotech #TechBio #DAO #HealthTech #DigitalHealth

TechBio is the "New Wave" 🚀 With the aid of remarkable enabling technologies such as #AI and #ML, we're unlocking the immense potential of biology to heal, to feed and to provide for ourselves and for our planet. BUT, the biopharma industry faces challenges in aligning incentives and funding. Academic labs often struggle to secure funding for early career researchers and risky projects. This is where platforms like Molecule AG and VitaDAO address these issues by creating open ecosystems for community-driven research funding. Molecule was started by Tyler Golato and Paul Kohlhaas. In our latest newsletter, we delve into two amazing topics: TechBio & Decentralised Biotechnology. https://lnkd.in/exZWAAr5 #Biotech #TechBio #DAO #HealthTech #DigitalHealth

🔍 Exploring the Rise of TechBio in Biotech! 🔬 Have you heard about the latest trend in biotech? Companies are rebranding themselves as "TechBio" to highlight their forward-thinking approach to integrating information technology into biological research. But what exactly does this mean, and how does it affect investors? Let's delve into the details! 💡💻 What is TechBio? TechBio, short for "technology" before "biology," signifies a shift in perspective towards treating scientific challenges as industrial engineering problems. Companies like Ginkgo Bioworks, Inc. , Recursion Pharmaceuticals, and Schrödinger are leading the charge by leveraging advanced technologies such as AI, machine learning, and laboratory robotics to streamline the research and development (R&D) process. This approach aims to create automated systems that minimize human intervention, reduce costs, and enhance efficiency in drug discovery and development. Is TechBio More Than Marketing? While TechBio may initially seem like a marketing buzzword, companies embracing this concept are genuinely revolutionizing drug development. With operations organized around automation technologies, they offer a distinct approach compared to traditional biotechs. However, investors should view TechBio as part of the broader biotech landscape, considering factors like financial stability, pipeline diversity, and industry collaborations. Investing in TechBio Stocks Investing in TechBio stocks follows similar principles to traditional biotech investments. Look for companies with strong financials, robust pipelines, reputable collaborators, and visionary leadership. Understand the inherent risks involved in biotech investments and conduct thorough due diligence before making decisions. As pioneers in their field, companies like Schrödinger, Ginkgo Bioworks, and Recursion exemplify the potential of TechBio in revolutionizing drug discovery. While the risks are high, their innovative approaches offer exciting opportunities for investors seeking growth in the biotech sector. 🌱💰 #TechBio #Biotech #Innovation #Investing #Biopharma #AI #MachineLearning #Robotics #DrugDiscovery #StockMarket #FinancialAdvice #InvestmentStrategy 💼🧬🤖

We are empowering breakthroughs in #biotechnology! Introducing the first of the 10 student #startups participating in our Startup Accelerator Program this spring: Biagon Molecular Engineering.   "With an aim to accelerate drug discovery, Biagon utilizes a proprietary machine learning algorithm to predict the biochemical activity of new drug leads- specializing in GPCR targeting. This breakthrough technology significantly reduces development cycles, making drug optimization more efficient and cost-effective for small-to-medium-sized biotech firms. Join us in celebrating innovation at the intersection of science and technology!"

This is a great read on how techbio companies really are different from classic biotech: by scaling data collection, modeling the processes of interest, and using those models to guide future data collection, good teams will end up with proprietary network effects.

It's been a couple days, but it's worth talking about because ESM3 is huge news. EvolutionaryScale, a new startup, has a $142 million seed round (NVentures, Amazon, Lux Capital, ex-Github CEO Nat Friedman) for a new generative LLM for protein design. ESM3 was trained on 2.78 billion natural proteins. Up to 98 billion parameters. They even designed a new GFP in their whitepaper, just because they could. Their whitepaper describes Geometric Attention, using an architecture of attention (i.e. like AlphaFold 2) but this time taking in coordinates of structure instead of sequence the way AF2 does. Link below. EvolutionaryScale's immediate plans are to make ESM3 available to pharma and biotech for drug discovery. There are 75 molecules that have been put into the clinic since 2015, and that number is expected to grow exponentially. Now with both ligand design (AF3) and protein design (ESM3) marketed to biotech companies by tech juggernauts, I'll be excited to see if pharma ROI can really make a comeback, and whether rare diseases can get a new place in the light with the efficiencies of computational design. How long until ESM3 drugs are in the clinic? Whitepaper here: https://lnkd.in/e_baegCM #biotech #pharma #drugdiscovery #patientexperience

💸 Impulsonics has closed its first funding round to advance the development of its unique biotech automation platform and begin customer trials. The SETsquared Bristol member and University of Bristol spin-out is developing a biotech automation platform using acoustic waves to manipulate cells non-invasively, within sterile containers. This breakthrough will allow for the simplification of crucial processes in cell culture, leading to the development of low-cost, high-throughput modular systems for automating key tasks such as cell passaging – the repetitive process of transferring cells from one container to another when the current one is full. The closure of its recent funding round from SFC Capital, British Business Investments, the University of Bristol and private angels highlights market confidence in Impulsonics’ mission to turn cutting edge scientific innovations into scalable processes for research and healthcare. Get the full story 👉 https://ow.ly/Yxpy50Ruu7M #Funding #Investment #Biotech

#MachineLearning and platform technologies like #genetherapy now dominate the biotech investment landscape. With Baltimore stakeholders focused on a phase 2 #techhub bid around AI & Biotech for precision health, the data shows that this is the direction investors are interested in as well. https://lnkd.in/eHxatcqe

With each new discovery, drug, diagnostic or intervention comes an opportunity for us to rethink and reshape the infrastructure necessary to make science possible. Discover the latest #lifesciences research and trends in our 2023 Life Sciences Industry and Real Estate Perspective-> #LifeScience #VCfunding #LabSpaceDemand #JLL #SanDiego #LabSpace #Biotech #LifeScience #Innovation #SandiegoCommericalRealEstate #USLifeScience #RealEstate

Prolific Machines, Inc. has raised $55 million for light-controlled bioreactors for a more precise method of cell growth. 'Months ago, we wrote about how Prolific Machines, one of IndieBio’s fastest-growing startups and the record-holder for fastest seed round in IndieBio history—has the key to cell cultured meat via its unique optogenetic approach. We still believe it (along with the technology’s potential for other applications in food and medicine), and tons of leading investors do, too—to the tune of $55 million in new Series B financing.' https://hubs.li/Q02CtK5W0